News
Pfizer boosted its profit outlook for the year following gains to its top- and bottom-line in its latest quarter.
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...
Pfizer stock rose after the drugmaker posted adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, ...
Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q2 CY2025, with sales up 10.3% year ...
Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.
The $3.00-a-share midpoint of its new range would put it just below the FactSet consensus estimate of $3.02 a share for Pfizer’s adjusted 2025 earnings.
Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
Pfizer has abanonded yet another GLP-1 drug from its shrinking obesity pipeline, as well as dumping a Clostridium difficile ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results